Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

172790

registered interest
date	08/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the studies recommended by the Human Fertilisation and Embryology Authority's expert review panel in the publication, Scientific review of the safety and efficacy of methods to avoid mitochondrial disease through assisted conception: update, published in March 2013 on mosaicism in human morulae have been concluded; and in which peer-reviewed journal his Department plans to publish the findings of those studies.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	220195
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that in its 2014 report the Expert Panel, convened by the HFEA, concluded that, in relation to mosaicism in human morulae:</p><p> </p><p> </p><p> </p><p>“Although experiments are already reported on ES cells and their derivatives with MST, further corroborative experiments would be valuable to demonstrate the degree of heteroplasmic mosaicism in morulae, and to provide data to address whether there was any amplification of mtDNA carried over.”</p><p> </p><p> </p><p> </p><p>The Panel’s report can be found on the HFEA’s website at:</p><p> </p><p> </p><p> </p><p>http://www.hfea.gov.uk/6896.html</p><p> </p><p> </p><p> </p><p>The “already reported” experiments were published in Nature in 2013.</p><p> </p><p> </p><p> </p><p>At the time of writing the 2014 report, to the Panel’s knowledge, this work had not been published in a peer-reviewed journal. The Department does not routinely publish scientific research conducted independently by others.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 13/01/2015 15:21:10 answering member 3918 label Biography information for Jane Ellison
tabling member	3958 label Biography information for Fiona Bruce

172792

registered interest
date	08/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: Birmingham
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the average waiting time is for talking therapy in Birmingham.
tabling member constituency	Birmingham, Erdington
tabling member printed	Jack Dromey
uin	220193
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>Information on the median waiting times for Improving Access to Psychological Therapies (IAPT) services by Clinical Commissioning Groups (CCGs) in Birmingham for 2013-14 is shown in the following table.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Number of referrals entering treatment</p></td><td><p>Median waiting time (days)</p></td></tr><tr><td><p>NHS Birmingham and South Central CCG</p></td><td><p>3,320</p></td><td><p>26</p></td></tr><tr><td><p>NHS Sandwell and West Birmingham CCG</p></td><td><p>5,135</p></td><td><p>25</p></td></tr><tr><td><p>NHS Birmingham Cross City CCG</p></td><td><p>9,020</p></td><td><p>29</p></td></tr></tbody></table><p> </p><p><em>Source: </em>Health and Social Care Information Centre (HSCIC), IAPT Dataset</p><p> </p><p> </p><p> </p><p><em>Notes:</em></p><p> </p><ol start="1" type="1"><li>It is not possible to separate Sandwell from NHS Sandwell and West Birmingham CCG; as such, data for Sandwell is also included in this response</li><li>The IAPT dataset contains information on referrals to IAPT services which provide talking therapies.</li><li>Waiting time is measured by counting the number of days between a referral being received and the first treatment appointment. Currently, the presence of a valid therapy type is used as an indicator of whether treatment was provided in the course of the appointment.</li><li>This data is based upon a count of referrals received by IAPT services, not distinct people. In order to be included in these figures, a referral must have had a first treatment appointment in the reporting period (1 April 2013 to 31 March 2014)</li></ol><p> </p><p><strong> </strong></p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 13/01/2015 15:33:09 answering member 1439 label Biography information for Norman Lamb
tabling member	3913 label Biography information for Jack Dromey

172797

registered interest
date	08/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether he plans to put contingency arrangements in place to ensure support for recipients of mitochondrial donation techniques in the event of failure or abnormal development in the resulting child.
tabling member constituency	North Tyneside
tabling member printed	Mrs Mary Glindon
uin	220183
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>There are already arrangements in place to support children born with conditions relating.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 13/01/2015 15:16:23 answering member 3918 label Biography information for Jane Ellison
tabling member	4126 label Biography information for Mary Glindon

172798

registered interest
date	08/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of whether eggs used in the creation of embryos through maternal spindle transfer or pronuclear transfer have had their mitochondrial or nuclear genes altered in the process.
tabling member constituency	North Tyneside
tabling member printed	Mrs Mary Glindon
uin	220181
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>Neither the nuclear DNA or mitochondrial DNA of the patient’s egg is altered during the creation of an embryo during mitochondrial donation treatment, using the maternal spindle transfer (MST) and pro-nuclear transfer (PNT) techniques.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 13/01/2015 15:21:06 answering member 3918 label Biography information for Jane Ellison
tabling member	4126 label Biography information for Mary Glindon

172799

registered interest
date	08/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the implications for public safety in relation to his policy on mitochondrial transfer of the study by Professor John Zhang et al, published in Fertility and Sterility, Vol 80, Suppl. 3, September 2003.
tabling member constituency	North Tyneside
tabling member printed	Mrs Mary Glindon
uin	220182
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>I refer the hon. Member to the answer given to the hon. Member for Congleton (Fiona Bruce) on 3 December 2014 to Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2014-11-26/216104/" target="_blank">216104</a>.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 13/01/2015 16:17:02 answering member 3918 label Biography information for Jane Ellison
tabling member	4126 label Biography information for Mary Glindon

172800

registered interest
date	08/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sick Leave
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many staff in (a) his Department and (b) each of its non-departmental public bodies were absent from work through sickness in December 2014.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	220225
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>The information requested is presented in the table below. For the Department’s executive non-departmental public bodies the information requested is not held centrally: consequently this data has been provided by the individual bodies.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p> </p><p>Name of organisation</p><p> </p></td><td><p>Number of staff absent from work through sickness during December 2014</p></td></tr><tr><td><p>Department of Health</p></td><td><p>195</p></td></tr><tr><td><p>NHS England</p></td><td><p>729</p></td></tr><tr><td><p>Monitor</p></td><td><p>36</p></td></tr><tr><td><p>Care Quality Commission</p></td><td><p>206</p></td></tr><tr><td><p>National Institute for Health and Care Excellence</p></td><td><p>111</p></td></tr><tr><td><p>Health and Social Care Information Centre</p></td><td><p>256</p></td></tr><tr><td><p>Human Fertilisation and Embryology Authority</p></td><td><p>5</p></td></tr><tr><td><p>Health Research Authority</p></td><td><p>23</p></td></tr><tr><td><p>Human Tissue Authority</p></td><td><p>4</p></td></tr></tbody></table><p> </p><p> </p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 13/01/2015 15:39:02 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	4036 label Biography information for Luciana Berger

172801

registered interest
date	08/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mesothelioma
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps the Government is taking to raise awareness of mesothelioma and its cause by (a) exposure to asbestos and (b) other causes.
tabling member constituency	Cambridge
tabling member printed	Dr Julian Huppert
uin	220226
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>The Health and Safety Executive (HSE) has run a number of asbestos related awareness raising campaigns including the ‘Hidden Killer’ campaign in 2008-09; the asbestos ‘Training Pledge’ in 2010; and the current ‘Beware Asbestos’ campaign.</p><p> </p><p> </p><p> </p><p>The ‘Beware Asbestos’ campaign was launched in October 2014 and is aimed at trades in which people who may disturb asbestos-containing materials in their day to day work. It includes information on identifying asbestos-containing materials and simple, easy to understand advice on how to avoid exposure to asbestos when carrying out a range of common work activities on such materials. It features a smartphone ‘app’ as a means of delivering this information to.</p><p> </p><p> </p><p> </p><p>HSE has guidance on the health risks from asbestos, including mesothelioma on its dedicated asbestos related web pages, together with comprehensive information on how to comply with the legal controls covering work with asbestos. This is available at</p><p> </p><p> </p><p> </p><p><a href="http://www.hse.gov.uk/asbestos" target="_blank">www.hse.gov.uk/asbestos</a></p><p> </p><p><strong> </strong></p><p> </p><p>Information about causes and symptoms of mesothelioma and advice on seeking help is also available on NHS Choices at</p><p> </p><p> </p><p><a href="http://www.nhs.uk/Livewell/Lungcancer/Pages/Asbestosandlungcancer.aspx" target="_blank">www.nhs.uk/Livewell/Lungcancer/Pages/Asbestosandlungcancer.aspx</a></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 13/01/2015 15:08:07 answering member 3918 label Biography information for Jane Ellison
tabling member	3931 label Biography information for Dr Julian Huppert

172802

registered interest
date	08/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the experiment on mitochondrial DNA carry-over on non-human primate model into the possible heteroplasmy of tissues in the foetus, recommended by the Human Fertilisation and Embryology Authority's expert panel in its publication Scientific review of the safety and efficacy of methods to avoid mitochondrial disease through assisted conception, published April 2011, has been concluded; and in which peer-reviewed journal he plans to publish the results of that experiment.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	220220
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that some relevant experiments have been carried out in the macaque a summary of which can be found at paragraph 2.3.4 of the 2013 report of the Expert Panel convened by the HFEA. The report can be found on the HFEA’s website at:</p><p> </p><p> </p><p> </p><p>http://www.hfea.gov.uk/6896.html</p><p> </p><p> </p><p> </p><p>The results were published in Cell Reports in 2012.</p><p> </p><p> </p><p> </p><p>The use of non-human primate experiments was deemed by the Panel, in its 2013 and 2014 reports, to no longer be necessary.</p><p> </p><p> </p><p> </p><p>The Department does not routinely publish scientific research conducted independently by others.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 13/01/2015 15:09:38 answering member 3918 label Biography information for Jane Ellison
tabling member	3958 label Biography information for Fiona Bruce

172805

registered interest
date	08/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the experiment on vitrifying zygotes created through pronuclear transfer, recommended by the Human Fertilisation and Embryology Authority's expert panel in its publication Scientific review of the safety and efficacy of methods to avoid mitochondrial disease through assisted conception, published in April 2011, has been concluded; and in which open access peer-reviewed journal he plans to publish the results of that experiment.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	220217
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that at the time of writing its 2014 report that to, the Expert Panel’s knowledge, convened by the HFEA, relevant results relating to these further had not been being published in a peer-reviewed journal.</p><p> </p><p> </p><p> </p><p>However, the Panel recognised that advances in cryopreservation are being made generally within the context of assisted reproduction technology.</p><p> </p><p> </p><p> </p><p>The Department does not routinely publish scientific research conducted independently by others.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 13/01/2015 16:16:42 answering member 3918 label Biography information for Jane Ellison
tabling member	3958 label Biography information for Fiona Bruce

172806

registered interest
date	08/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the experiments on human embryonic stem cells derived from blastocysts that are heteroplasmic for abnormal mitochondrial DNA (mtDNA) and blastocysts created through maternal spindle transfer and pronuclear transfer where the oocytes had abnormal mtDNA, recommended by the Human Fertilisation and Embryology Authority's expert panel in its publication Scientific review of the safety and efficacy of methods to avoid mitochondrial disease through assisted conception, published April 2011, has been concluded; and in which peer-reviewed journal he plans to publish the results of those experiments.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	220218
answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that the Expert Panel it convened revised this recommended research to the following, as outlined in its 2013 and 2014 reports:</p><p> </p><p> </p><p> </p><p>“Tests for heteroplasmy should be carried out on primordial germ cells obtained from human ES cells derived from blastocysts created through MST and PNT where the oocytes had variant or abnormal mtDNA. If primordial germ cell derivation is not possible or limitations in the model undermine its utility, clonal analysis of single cell-derived human ES cells could be used. Comparisons beginning with blastocysts known to be heteroplasmic for variant or abnormal mtDNA would be informative. This recommendation still stands.”</p><p> </p><p> </p><p> </p><p>The Panel’s reports can be found on the HFEA’s website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.hfea.gov.uk/6896.html" target="_blank">http://www.hfea.gov.uk/6896.html</a></p><p> </p><p> </p><p> </p><p>The Panel’s rationale regarding experiments using abnormal mitochondria is outlined at section 3.5 of their 2014 report.</p><p> </p><p> </p><p> </p><p>At the time of writing the 2014 report, to the Panel’s knowledge, this work had not been published in a peer-reviewed journal.</p><p> </p><p> </p><p> </p><p>The Department does not routinely publish scientific research conducted independently by others.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 13/01/2015 15:35:26 answering member 3918 label Biography information for Jane Ellison
tabling member	3958 label Biography information for Fiona Bruce